MAP2K5
Mitogen-Activated Protein Kinase Kinase 5
Gene Information Card
| Symbol | MAP2K5 |
|---|---|
| Full Name | Mitogen-Activated Protein Kinase Kinase 5 |
| Gene Type | protein-coding |
| Chromosomal Location | 15q23 |
| NCBI Gene ID | 5607 ncbi.nlm.nih.gov/gene/5607 |
| Ensembl ID | ENSG00000137868 |
| UniProt ID | Q13163 |
| OMIM ID | 602520 |
| HGNC ID | 6846 |
| Aliases | MEK5, MAPKK5, PRKMK5 |
Description
MAP2K5 (MEK5) is a dual-specificity protein kinase that specifically phosphorylates and activates MAPK7 (ERK5). It functions in the MAPK signaling cascade, regulating cell proliferation, differentiation, and survival. MAP2K5 is activated by upstream kinases such as MAP3K2/3 and is involved in neurodevelopment, cardiac function, and cancer progression.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Cancer (various) | MAP2K5 overexpression or activating mutations drive ERK5 signaling, promoting proliferation and metastasis. | COSMIC, ClinVar |
| Neurodevelopmental disorders | Missense variants in MAP2K5 have been associated with intellectual disability and developmental delay. | ClinVar, OMIM |
| Cardiac hypertrophy | MAP2K5-ERK5 pathway is implicated in cardiomyocyte growth and stress responses. | NCBI Gene, PubMed |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 12.5 | Medium |
| Heart | 9.8 | Medium |
| Skeletal Muscle | 7.2 | Low |
| Lung | 6.1 | Low |
| Liver | 3.4 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK293 | 15.2 | High expression |
| HeLa | 10.5 | Moderate expression |
| A549 | 8.9 | Moderate expression |
| MCF7 | 6.3 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1015C>T (p.Arg339Trp) | Missense | <0.1% | Unknown; reported in neurodevelopmental disorder |
| c.1246G>A (p.Glu416Lys) | Missense | <0.1% | Potential gain-of-function in cancer |
| Amplification | Copy number gain | 1-2% in breast cancer | Increased MAP2K5 expression |
Mutation functional classification
Loss of Function (LOF)
Rare missense variants (e.g., p.Arg339Trp) may reduce kinase activity, linked to neurodevelopmental phenotypes.
Gain of Function (GOF)
Amplification or activating mutations (e.g., p.Glu416Lys) enhance ERK5 signaling, promoting oncogenesis.
Dominant Negative (DN)
Not well characterized; some engineered mutants can inhibit ERK5 activation.
View complete mutation data：
Gene Ontology (GO)
| • MAP kinase kinase activity | • protein serine/threonine kinase activity |
| • ATP binding | • signal transduction |
| • MAPK cascade | • regulation of cell proliferation |
Pathways
• MAPK signaling pathway (KEGG: hsa04010)
• ERK5 signaling (Reactome: R-HSA-198753)
Protein Summary
MAP2K5 (MEK5) is a 448-amino acid dual-specificity kinase that phosphorylates ERK5 on Thr218/Tyr220. It contains an N-terminal PB1 domain for interaction with upstream MAP3Ks and a C-terminal kinase domain. MEK5 is critical for ERK5-mediated transcription and cellular responses to growth factors and stress.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| MAP2K5 Knockout HEK293 Cell Line | EDJ-KQ1105 | Human | 5607 | Details Get a Quote |
| MAP2K5 Knockout HeLa Cell Line | EDJ-KQ18937 | Human | 5607 | Details Get a Quote |
| MAP2K5 Knockout A-549 Cell Line | EDJ-KQ20285 | Human | 5607 | Details Get a Quote |
| MAP2K5 Knockout HCT 116 Cell Line | EDJ-KQ20286 | Human | 5607 | Details Get a Quote |
